CA2380953A1 - Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central - Google Patents

Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central Download PDF

Info

Publication number
CA2380953A1
CA2380953A1 CA002380953A CA2380953A CA2380953A1 CA 2380953 A1 CA2380953 A1 CA 2380953A1 CA 002380953 A CA002380953 A CA 002380953A CA 2380953 A CA2380953 A CA 2380953A CA 2380953 A1 CA2380953 A1 CA 2380953A1
Authority
CA
Canada
Prior art keywords
cells
polypeptide
growth factor
neural
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002380953A
Other languages
English (en)
Inventor
Evan Y. Snyder
Seth P. Finklestein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Childrens Medical Center Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2380953A1 publication Critical patent/CA2380953A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés, des trousses et des compositions servant à favoriser le rétablissement d'un sujet suite à une lésion du système nerveux central. Dans certains aspects, les procédés de l'invention comportent l'administration de cellules et d'un neurostimulant à un sujet. Le rétablissement peut se manifester par des améliorations des capacités neuromotrices ou cognitives, p. ex. un contrôle et des mouvements améliorés des membres ou une capacité d'expression améliorée. Dans certaines formes de réalisation, les procédés mentionnés peuvent faire partie d'un traitement de lésions résultant d'une ischémie, d'une hypoxie ou d'un traumatisme.
CA002380953A 1999-08-18 2000-08-18 Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central Abandoned CA2380953A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14956199P 1999-08-18 1999-08-18
US60/149,561 1999-08-18
PCT/US2000/022843 WO2001012236A2 (fr) 1999-08-18 2000-08-18 Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central

Publications (1)

Publication Number Publication Date
CA2380953A1 true CA2380953A1 (fr) 2001-02-22

Family

ID=22530841

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002380953A Abandoned CA2380953A1 (fr) 1999-08-18 2000-08-18 Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central

Country Status (10)

Country Link
EP (1) EP1210106A2 (fr)
JP (1) JP2003507349A (fr)
CN (1) CN1753686A (fr)
AU (1) AU6790300A (fr)
BR (1) BR0013388A (fr)
CA (1) CA2380953A1 (fr)
IL (1) IL148175A0 (fr)
MX (1) MXPA02001719A (fr)
NO (1) NO20020779L (fr)
WO (1) WO2001012236A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021668D0 (en) * 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
DE10111486A1 (de) * 2001-03-09 2002-10-02 Ralph R Dawirs Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7687505B2 (en) * 2002-01-14 2010-03-30 Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
US7432243B2 (en) * 2002-04-08 2008-10-07 The Scripps Research Institute Truncated 24kDa basic fibroblast growth factor
US7153256B2 (en) 2003-03-07 2006-12-26 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
US8118722B2 (en) 2003-03-07 2012-02-21 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
US7651459B2 (en) 2004-01-06 2010-01-26 Neuronetics, Inc. Method and apparatus for coil positioning for TMS studies
US8177702B2 (en) 2004-04-15 2012-05-15 Neuronetics, Inc. Method and apparatus for determining the proximity of a TMS coil to a subject's head
US7601115B2 (en) 2004-05-24 2009-10-13 Neuronetics, Inc. Seizure therapy method and apparatus
WO2006023530A2 (fr) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions et procedes permettant d'ameliorer le systeme structurel et fonctionnel de la reorganisation et de la recuperation du systeme nerveux
US7857746B2 (en) 2004-10-29 2010-12-28 Nueronetics, Inc. System and method to reduce discomfort using nerve stimulation
US8088058B2 (en) 2005-01-20 2012-01-03 Neuronetics, Inc. Articulating arm
US7396326B2 (en) 2005-05-17 2008-07-08 Neuronetics, Inc. Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators
US7824324B2 (en) 2005-07-27 2010-11-02 Neuronetics, Inc. Magnetic core for medical procedures
US20070135859A1 (en) * 2005-12-09 2007-06-14 Peter Eriksson Use of transcranial magnetic stimulation to improve memory and stress related syndromes in humans
KR101467136B1 (ko) 2006-06-02 2014-12-01 화이자 프로덕츠 인코포레이티드 순환 종양 세포 분석
DE102007003565B4 (de) 2007-01-24 2012-05-24 Forschungszentrum Jülich GmbH Vorrichtung zur Reduktion der Synchronisation neuronaler Hirnaktivität sowie dafür geeignete Spule
US9884200B2 (en) 2008-03-10 2018-02-06 Neuronetics, Inc. Apparatus for coil positioning for TMS studies
EP2326330B1 (fr) 2008-09-16 2015-01-07 University Of Central Florida Research Foundation, Inc. Compositions pour traiter et retarder le début de chute de cheveux
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
CN103230581B (zh) * 2011-11-10 2016-12-21 陈锦辉 用于治疗创伤性脑损伤的组合物和方法
CN103421800B (zh) * 2013-09-05 2015-07-22 新乡医学院 用于治疗脊髓损伤的重组基因、重组载体和重组细胞
CN103555747B (zh) * 2013-10-22 2015-04-08 深圳先进技术研究院 胶质细胞bFGF表达提高系统及其构建方法和应用
US10391149B2 (en) * 2014-08-15 2019-08-27 National Health Research Institutes Methods to enhance nerve regeneration utilizing neural stem cells and IL12P40

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
EP0749472B1 (fr) * 1994-03-07 2004-08-11 Immunex Corporation Culture de cellules extra-corporelle et trousses de transplantation
ATE244574T1 (de) * 1996-03-22 2003-07-15 Curis Inc Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
US20020136705A1 (en) * 1998-06-30 2002-09-26 Jonathan Dinsmore Porcine spinal cord cells and their use in spinal cord repair
CA2373808C (fr) * 1999-05-14 2011-04-19 Henry Ford Health System Transplantation de moelle osseuse pour traiter les lesions du systeme nerveux central

Also Published As

Publication number Publication date
NO20020779L (no) 2002-04-15
IL148175A0 (en) 2002-09-12
JP2003507349A (ja) 2003-02-25
CN1753686A (zh) 2006-03-29
NO20020779D0 (no) 2002-02-15
MXPA02001719A (es) 2003-09-25
BR0013388A (pt) 2002-08-27
AU6790300A (en) 2001-03-13
EP1210106A2 (fr) 2002-06-05
WO2001012236A3 (fr) 2001-08-30
WO2001012236A2 (fr) 2001-02-22
WO2001012236A9 (fr) 2002-09-06

Similar Documents

Publication Publication Date Title
CA2380953A1 (fr) Procedes, compositions et trousses pour favoriser le retablissement suite a une lesion du systeme nerveux central
US6749850B1 (en) Methods, compositions and kits for promoting recovery from damage to the central nervous system
US20190224247A1 (en) Methods and compositions for provision of angiogenic factors
Germani et al. Vascular endothelial growth factor modulates skeletal myoblast function
US20050169896A1 (en) Bone marrow transplantation for treatment of stroke
US8940293B2 (en) Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
EP1617852B1 (fr) Cellules musculaires derivees favorisant et ameliorant la reparation et la regeneration des nerfs
US9072740B2 (en) Methods of improving central nervous system functioning
JP2002530067A (ja) 細胞の低酸素培養
JP2006070040A (ja) 哺乳類の神経の増殖を促進する薬物
BRPI0620523A2 (pt) método de aumentar o potencial de implante e de atração celular, método de preparar células para transplante em um sujeito, população de células e composição farmacêutica
EP1511511A2 (fr) Utilisation d'il-19, d'il-22 et d'il-24 pour le traitement des troubles hematopoietiques
WO2020013090A1 (fr) Procédé de production de cellules de type neurone
KR20010033834A (ko) 면역 특권 부위의 생성을 위한 착색된 망막 상피 세포의사용
Chen et al. Neurotrophin-3 stimulates migration of mesenchymal stem cells overexpressing TrkC
US20030104995A1 (en) Neuroprotective methods and compositions
JP2003512333A (ja) 脳における移植された前駆体細胞のインビボ増殖および移動を誘導するための方法
Zhu et al. Hydrogel-based microenvironment engineering of haematopoietic stem cells
Al‐Kharboosh et al. Therapeutic potential and impact of nanoengineered patient‐derived mesenchymal stem cells in a murine resection and recurrence model of human glioblastoma
US20190382728A1 (en) Menstrual Blood Derived Angiogenesis Stimulatory Cells
WO2022224230A1 (fr) Traitement d'états médicaux par des greffes de cellules souches et activation de cellules souches
Li A study of hematopoietic and endothelial potentials of long-term cultured murine embryonic yolk sac cells and the establishment of an in vitro angiogenesis system
Woodhall Olfactory ensheathing cell phenotype after implantation into the lesioned spinal cord
Sahni Mechanisms regulating astrogliosis and functional recovery following spinal cord injury

Legal Events

Date Code Title Description
FZDE Discontinued